|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquisition
|
gptkb:Zymeworks
gptkb:Acorda_Therapeutics
gptkb:Idec_Pharmaceuticals
gptkb:Onco_Immune
Nightstar Therapeutics
|
|
gptkbp:ceo
|
gptkb:Michel_Vounatsos
gptkb:George_Scangos
|
|
gptkbp:clinical_trial
|
gptkb:amyotrophic_lateral_sclerosis
gptkb:muscular_dystrophy
gptkb:neurodegenerative_diseases
gptkb:multiple_sclerosis
|
|
gptkbp:employees
|
7,000 (2020)
|
|
gptkbp:focus
|
neurological diseases
|
|
gptkbp:founded
|
gptkb:1978
|
|
gptkbp:founder
|
M. A. (Marty) Dyer
|
|
gptkbp:headquarters
|
gptkb:Cambridge,_Massachusetts
Cambridge, Massachusetts, USA
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Biogen Idec Ltd.
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:market_cap
|
$40 billion (2020)
|
|
gptkbp:partnership
|
gptkb:Genentech
gptkb:Samsung_Bioepis
gptkb:Takeda_Pharmaceutical_Company
gptkb:Alnylam_Pharmaceuticals
gptkb:Astra_Zeneca
gptkb:Sanofi
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Regeneron_Pharmaceuticals
gptkb:Merck_&_Co.
gptkb:Roche
gptkb:Amgen
gptkb:Gilead_Sciences
gptkb:Eisai
gptkb:Vertex_Pharmaceuticals
gptkb:Ionis_Pharmaceuticals
gptkb:Abb_Vie
gptkb:Celgene
gptkb:Sarepta_Therapeutics
gptkb:Novartis
|
|
gptkbp:products
|
gptkb:Tecfidera
gptkb:Avonex
gptkb:Tysabri
|
|
gptkbp:research_focus
|
gptkb:neurodegenerative_diseases
neuroinflammation
pain management
psychiatric disorders
neuroimmunology
|
|
gptkbp:revenue
|
$13.45 billion (2020)
|
|
gptkbp:stock_symbol
|
gptkb:BIIB
|
|
gptkbp:subsidiary
|
gptkb:Biogen_Idec_International_Gmb_H
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
www.biogen.com
|
|
gptkbp:bfsParent
|
gptkb:Biogen_Idec
|
|
gptkbp:bfsLayer
|
5
|